Literature DB >> 8132739

Anticardiolipin antibodies are elevated in drug-free, multiply affected families with schizophrenia.

M Firer1, P Sirota, K Schild, A Elizur, H Slor.   

Abstract

The objective of this study was to measure anticardiolipin antibodies in patients and healthy relatives in multicase families with schizophrenia. Twenty-eight (28) multicase families with schizophrenia were examined. One hundred three drug-free patients and 66 first-degree relatives consented to evaluation by DSM-III-R criteria. Criteria for patient definition included the following: age > or = 16, a confirmed hospital diagnosis of schizophrenia, knowledge of biological parents, and consent to participate. Additional data were drawn from family history and medical records. Serum samples were tested separately for IgG and IgM anticardiolipin by enzyme-linked immunosorbent assay (ELISA) and designated positive/negative by comparison to the reactivity of an age-matched control group. IgG anticardiolipin antibodies were significantly more common in both patients and relatives compared to controls. IgM anticardiolipin antibodies were significantly more common in patients. In 75% of families at least one member was anticardiolipin positive and this positivity correlated with patient positivity. The relevance of anticardiolipin antibodies in both patients and healthy relatives of some multicase families to the pathogenesis of schizophrenia is discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8132739     DOI: 10.1007/bf01541177

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  22 in total

1.  Special report. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group.

Authors:  E N Harris
Journal:  Am J Clin Pathol       Date:  1990-10       Impact factor: 2.493

Review 2.  Antiphospholipid antibodies and "syndromes": many questions and few answers.

Authors:  R A Asherson
Journal:  Isr J Med Sci       Date:  1990-05

3.  New aspects of anticardiolipin antibodies.

Authors:  H P McNeil; J E Hunt; S A Krilis
Journal:  Clin Exp Rheumatol       Date:  1990 Nov-Dec       Impact factor: 4.473

4.  Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.

Authors:  M Galli; P Comfurius; C Maassen; H C Hemker; M H de Baets; P J van Breda-Vriesman; T Barbui; R F Zwaal; E M Bevers
Journal:  Lancet       Date:  1990-06-30       Impact factor: 79.321

5.  Anticardiolipin antibodies and binding of anionic phospholipids and serum protein.

Authors:  E N Harris; S Pierangeli; J Barquinero; J Ordi-Ros
Journal:  Lancet       Date:  1990-08-25       Impact factor: 79.321

6.  Immunologic and coagulation disorders in chlorpromazine-treated patients.

Authors:  M H Zarrabi; S Zucker; F Miller; R M Derman; G S Romano; J A Hartnett; A O Varma
Journal:  Ann Intern Med       Date:  1979-08       Impact factor: 25.391

Review 7.  Antiphospholipid antibody syndrome: immunologic and clinical aspects.

Authors:  L R Sammaritano; A E Gharavi; M D Lockshin
Journal:  Semin Arthritis Rheum       Date:  1990-10       Impact factor: 5.532

8.  Autoantibodies to DNA in multicase families with schizophrenia.

Authors:  P Sirota; M A Firer; K Schild; A Tanay; A Elizur; D Meytes; H Slor
Journal:  Biol Psychiatry       Date:  1993-03-15       Impact factor: 13.382

9.  High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population.

Authors:  M N Manoussakis; A G Tzioufas; M P Silis; P J Pange; J Goudevenos; H M Moutsopoulos
Journal:  Clin Exp Immunol       Date:  1987-09       Impact factor: 4.330

10.  Anticardiolipin antibodies in unselected autoimmune rheumatic disease patients.

Authors:  M N Manoussakis; A E Gharavi; A A Drosos; R C Kitridou; H M Moutsopoulos
Journal:  Clin Immunol Immunopathol       Date:  1987-09
View more
  5 in total

1.  The presence of lupus anticoagulant and anticardiolipin antibodies in patients undergoing long-term neuroleptic treatment.

Authors:  M Schwartz; M Rochas; E Toubi; B Sharf
Journal:  J Psychiatry Neurosci       Date:  1999-09       Impact factor: 6.186

Review 2.  Antipsychotic-induced venous thromboembolism: a review of the evidence.

Authors:  Staffan Hägg; Olav Spigset
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

3.  Differences in the natural autoantibody patterns of patients with schizophrenia and normal individuals.

Authors:  P Lévy-Soussan; A Berneman; M F Poirier; A Galinowski; H Loo; J P Olié; S Avrameas
Journal:  J Psychiatry Neurosci       Date:  1996-03       Impact factor: 6.186

Review 4.  Venous thromboembolism in recipients of antipsychotics: incidence, mechanisms and management.

Authors:  Anna K Jönsson; Olav Spigset; Staffan Hägg
Journal:  CNS Drugs       Date:  2012-08-01       Impact factor: 5.749

Review 5.  Anti-phospholipid syndrome associated with schizophrenia description of five patients and review of the literature.

Authors:  Pikman Regina; Rotman Pnina; Aiman Natur; Levy Yair
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.